India’s CDMO market set to double by 2028 amid Asia’s healthcare boom

This surge is driven by India’s strong position in Active Pharmaceutical ingredients (API) and generic drug manufacturing, along with cost advantages over China.

Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *